メールサービス キャンペーン : 期間中に新規登録や配信希望カテゴリの変更等をされた方に、ご用意した無料レポートを提供しております。 新規登録 / 登録内容変更

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

バイオ医薬品の世界市場

Biopharmaceuticals

発行 Global Industry Analysts, Inc. 商品コード 335296
出版日 ページ情報 英文 730 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.61円で換算しております。

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

Back to Top
バイオ医薬品の世界市場 Biopharmaceuticals
出版日: 2015年05月01日 ページ情報: 英文 730 Pages
概要

当レポートでは、世界のバイオ医薬品市場について調査し、業界・製品の概要や、世界市場の全体的見通し (直近・今後の7年間の推定値・予測値)、最近の市場動向、部門別および各地域・主要国市場の詳細動向などを分析すると共に、主な企業プロファイル (全514社分) をも盛り込んでお届けいたします。

第1章 イントロダクション・調査方法・製品定義

第2章 エグゼクティブ・サマリー

  • 産業概要
    • 生物製剤:従来型の医薬品市場に取って代わる存在
    • 現状・将来性の分析
    • 市場競争
    • 特許満了の状況 (2015年)
    • 市場促進要因
    • 市場抑制要因
    • バイオ医薬品の製品上市の動き (2014〜2015年)
    • 研究開発 (R&D) 資金調達の重要性
  • 部門別分析
    • モノクローナル抗体:最も発展している分野
    • インスリン:高い潜在性のある分野
    • 遺伝子組み換え型治療用タンパク質
    • ワクチン市場のダイナミクス
  • 開発パイプライン上のバイオ医薬品
    • 開発中のインスリン製品
  • 市場の傾向
    • 製造現場で好まれている使い捨て型システム
    • バイオシミラーの重要性の拡大
    • サプライチェーン管理:治験における重要性
    • 植物由来製品の哺乳類細胞培養システムに対する優位性
    • 赤血球生成促進剤 (ESA) に関する安全上・効率上の課題
    • hMSCベース療法に伴う、増殖因子のニーズ拡大
    • 肝細胞療法の人気拡大
    • コスト効率的な手法の開発:目下の課題
    • 企業合併・買収 (M&A) 活動は引き続き活発
    • 長期的な成功を決定する要因
    • イノベーション
  • バイオ医薬品:概要
    • バイオ医薬品の製造・保存に関する規制環境
    • 用語集
    • バイオ医薬品の進化
    • バイオ医薬品の製造方法
    • バイオ医薬品の生産に関する主な懸念事項
    • 将来のバイオ医薬品の製造方法
    • バイオ医薬品の技術的特徴
    • バイオ医薬品の種類
      • インスリン
      • モノクローナル抗体
      • 遺伝子組み換え型タンパク質
      • ワクチン
  • 製品開発・発売 (全14件)
  • 最近の業界活動 (全29件)
  • 主要企業の分析
    • AbbVie, Inc. (米国)
    • Anavex Life Sciences Corp. (米国)
    • Baxter International, Inc. (米国)
    • Bayer HealthCare Pharmaceuticals, Inc. (米国)
    • Biocon (インド)
    • Eli Lilly (米国)
    • F. Hoffmann-La Roche Ltd. (Switzerland)
      • Genentech (米国)
    • GlaxoSmithKline (英国)
    • Janssen Biotech, Inc. (米国)
    • Kemwell Biopharma (インド)
    • Novartis (スイス)
      • Sandoz
    • Pfizer, Inc. (米国)
    • Sun Pharmaceutical Industries Ltd. (インド)
    • Sanofi S.A. (フランス)
  • 世界市場の見通し
    • 製品セグメント別の詳細

第3章 市場

  • 米国
  • カナダ
  • 日本
  • 欧州
    • フランス
    • ドイツ
    • イタリア
    • 英国
    • スペイン
    • ロシア
    • 他の欧州諸国
  • アジア太平洋地域
  • 他の国々 (RoW)

第4章 競争環境

目次
Product Code: MCP-7003

This report analyzes the worldwide markets for Biopharmaceuticals in US$ Million by the following Segments: Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 514 companies including many key and niche players such as -

AbbVie, Inc.
Anavex Life Sciences Corp.
Baxter International, Inc.
Bayer HealthCare Pharmaceuticals, Inc.
Biocon

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study
    • A. Recombinant Protein
    • B. Monoclonal Antibodies (mAbs)
    • C. Insulin
    • D. Vaccines

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Biologics: Taking over the Conventional Drugs Market
    • Table 1: Increasing Share of Biologics in the Global Pharmaceutical Market: 2013-2020 (includes corresponding Graph/Chart)
    • Table 2: Percentage Share of Pipeline Drugs for Biologics vs. Small Molecules (2014) (includes corresponding Graph/Chart)
  • Current and Future Analysis
  • Competition
    • Table 3: Leading Players in the Global Biopharmaceuticals Market (2014E): Percentage Market Share Breakdown of Value Sales for AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, Novo Nordisk, Pfizer, Roche, Sanofi, and Others (includes corresponding Graph/Chart)
    • Table 4: Leading Brands in the Global Biopharmaceuticals Market (2014E): Percentage Market Share Breakdown of Revenues for Avastin, Enbrel, Herceptin, Humira, Lantus, Lucentis, Neulasta, Novolog/NovoRapid, Remicade, Rituxan, and Others (includes corresponding Graph/Chart)
  • Intensifying Consolidation Activity
  • Recent M&A Activity in the Biologics Industry: 2014 & 2015
  • 2015: A year of Patent Expiries for Biologics
  • Patent Expiries of Major Biopharmaceutical Drugs in the US and Europe
  • Market Drivers
  • Growing Aging Population
    • Table 5: Global Population Statistics for the 65+ Age Group: 2013 (includes corresponding Graph/Chart)
    • Table 6: Life Expectancy by Select Countries: 2013 (includes corresponding Graph/Chart)
  • Market Restraints
  • Affordability
  • Complex Supply Chain
  • Quality and Regulatory Issues
  • 2014-15: A Launch-Driven Period for Biopharmaceuticals
  • Recently Approved Biopharmaceuticals: 2013, 2014 & 2015
  • R&D Funding Crucial
    • Table 7: Global Biopharmaceutical R&D Expenditure: 2010- 2015E (includes corresponding Graph/Chart)

2. SEGMENT ANALYSIS

  • Monoclonal Antibodies - The Most Viable Biopharmaceutical Segment
    • Table 8: Global Monoclonal Antibody Market by Leading Player (2014E) - Percentage Share of Value Sales for AbbVie, Amgen, Johnson & Johnson, Novartis, Pfizer, Roche, and Others (includes corresponding Graph/Chart)
    • Table 9: Global Monoclonal Antibody Market by Leading Brand (2014E) - Percentage Share of Value Sales for Avastin, Enbrel, Herceptin, Humira, Remicade, Rituxan, and Others (includes corresponding Graph/Chart)
  • Approved Monoclonal Antibodies for Therapeutic Use: 1986-2014
  • Opportunity Indicators
    • Cancer Incidence
    • Table 10: World Cancer Incidence by Geographic Region and Gender (2012): Number of New Cancer Cases Reported in Thousands for Asia-Oceania, Europe, North America, Latin America & the Caribbean, and Africa (includes corresponding Graph/Chart)
    • Table 11: World Cancer Mortality by Geographic Region and Gender (2012): Number of Cancer-Related Deaths in Thousands for Asia-Oceania, Europe, North America, Latin America & the Caribbean, and Africa (includes corresponding Graph/Chart)
    • Rheumatoid Arthritis Prevalence
    • Table 12: Projections of Rheumatoid Arthritis Prevalence in the US in Millions (2010-2030) (includes corresponding Graph/Chart)
    • Table 13: Prevalence of Treated Rheumatoid Arthritis in South Africa (Rate per 1000 Beneficiaries): 2008-2013 (includes corresponding Graph/Chart)
  • Insulin - Segment with High Potential
  • Competitive Landscape
    • List of Different Insulin Brands of the Three Major Players by Type
    • Table 14: Global Insulin Market by Brand (2014E): Percentage Share of Value sales for Apidra, Humalog, Humulin, Insuman, Lantus, Levimir, NovoMix, NovoRapid, and Others (includes corresponding Graph/Chart)
    • Comparative Analysis of New Insulin Basal Analogs
    • Table 15: Global Basal Insulin Market by Brand (2016-2020E): Percentage Market Share Breakdown of Revenues for Basalgar, Lantus, Levemir, Peg Lispro, Toujeo, and Tresiba (includes corresponding Graph/Chart)
  • Opportunity Indicator
    • Diabetes Prevalence & Incidence
    • Table 16: Global Diabetes Mellitus Prevalence by Geographic Region (2014E & 2035P): Prevalence (in Millions) and Percentage Share (includes corresponding Graph/Chart)
    • Table 17: Percentage Increase in DM Incidence among Ages 20-79 Worldwide by Geographic Region: 2013-2035 (includes corresponding Graph/Chart)
    • Table 18: Top Ten Countries Worldwide with the Highest Number of People (in the Age Group 20-79 Years) with DM (in Millions): 2014E & 2035P (includes corresponding Graph/Chart)
  • Recombinant Therapeutic Proteins
  • Anemia in CKD and Cancer Patients: Opportunity for EPO Therapy
  • Blood Growth Factors: Improving Circulation & Mobility in Peripheral Artery Disease Patients
  • Wound Management Market and Cellular Growth Factors
  • Multiple Sclerosis Drugs Market: Competition Set to Intensify
  • Interferon-based Drugs for HCV Treatment: An Insight
  • Vaccine Market Dynamics
    • Table 19: Global Vaccines Market by Leading Player (2014) - Percentage Share of Value Sales for GSK, Merck, Novartis Flu Vaccines, Pfizer, Sanofi, SP-MSD & Others (includes corresponding Graph/Chart)
  • Growth Drivers in a Capsule
  • Pediatric Vaccines: A Lucrative Segment
    • Table 20: Number of Reported Cases for Vaccine-Preventable Diseases Globally: 2009-2013 (includes corresponding Graph/Chart)
    • Table 21: Global Pediatric Vaccines Market by Leading Players (2013): Percentage Market Share Breakdown of Dollar Sales for GlaxoSmithKline, Novartis, Sanofi-Pasteur, Merck, and Others (includes corresponding Graph/Chart)
  • Hepatitis B Combination Vaccines to Propel Market Growth
  • Conjugated and Protein-based Vaccines to Take over Polysaccharide Vaccines for Infectious Diseases
  • DNA Vaccines: Engineering Growth

3. BIOPHARMACEUTICALS IN THE PIPELINE

    • Table 22: Biopharmaceutical Products' Pipeline by Therapeutic Category (2015) (includes corresponding Graph/Chart)
    • Table 23: No. of Pipeline Biopharmaceuticals for Cancer by Site (2015) (includes corresponding Graph/Chart)
    • Table 24: No. of Pipeline Biopharmaceuticals for HIV/AIDS Treatment by Type of Therapy (2015) (includes corresponding Graph/Chart)
  • Insulin Products in Development
  • List of Newly Approved and Pipeline Insulin Products: 2015

4. MARKET TRENDS

  • Disposable Systems Favored for Manufacturing
  • Innovations in Single-use Systems
  • Increasing Appeal of Biosimilars
    • Table 25: Global Biosimilars Market Size Estimates and Forecasts: 2012-2018F (includes corresponding Graph/Chart)
  • Supply Chain Management Crucial for Clinical Trials
  • Plant-based Production Scores over Mammalian Cell Culture Systems
  • Safety & Efficacy Issues Concerning Erythropoietin Stimulating Agents (ESAs)
  • hMSC-based Therapies to Drive Need for Growth Factors
  • Stem Cell Therapies Gain Popularity
  • Development of Cost Effective Methods - Need of the Hour
  • M&A Activity to Maintain Momentum
  • Key Factors Determining Long-Term Success
  • Innovations
  • Peptide against Skin Cancer
  • Monoclonal Antibodies to Treat Ebola

5. BIOPHARMACEUTICALS - AN OVERVIEW

  • Regulatory Environment for Biopharmaceuticals' Manufacture & Storage
  • Glossary of Terms
  • Evolution of Biopharmaceuticals
  • Biopharmaceutical Manufacturing
  • Bioprocess Membrane Technology
  • Disposable Manufacturing with Single-Use Systems
  • Major Concerns Related to the Production of Biopharmaceuticals
  • Future of Biopharmaceutical Manufacturing
  • Marketing Approval for Biopharmaceuticals
  • Techniques to Characterize Biopharmaceuticals
  • Biopharmaceuticals - Types and Therapeutic Applications
  • Insulin
  • Monoclonal Antibodies
  • Recombinant Proteins
    • Cytokines
    • Interferon
    • Colony Stimulating Factors (CSF)
    • Erythropoietin (EPO)
    • Clotting Factors
  • Vaccines
    • Types of Vaccines
      • Live, Attenuated Vaccines
      • Combination Vaccines
      • Killed or Inactivated Vaccines
      • DNA & Recombinant DNA Vaccines
      • Toxoids
      • Subunit Vaccines

6. PRODUCT LAUNCHES/APPROVALS

  • Mexican Health Authority, COFEPRIS, Approves Biocon's Insulin Glargine
  • Shantha Biotechnics Delivers 400,000 doses of Shan5 Vaccine
  • Amyris to Launch µPharm platform for Biotherapeutics Production
  • FDA Approves IMBRUVICA for New Indication
  • FDA Approves Cosentyx™ by Novartis
  • Hospira Submits BLA for the Biosimilar Retacrit
  • Celestial Biolabs to Launch Antibiotic for Diabetes
  • MHRA Validates RedHill Biopharma's Bekinda MAA
  • Zydus Cadila Launches Adalimumab Biosimilar
  • EPIRUS Launches Infimab
  • KYTHERA Biopharmaceuticals Submits NDS for ATX-101
  • FDA Accepts New Drug Application of KYTHERA's ATX-101
  • FDA Approves sNDA for Lymphoseek by Navidea
  • Hospira's Biosimilar Inflectra Launched in Central and Eastern Europe

7. RECENT INDUSTRY ACTIVITY

  • Sun Pharmaceuticals Integrates Ranbaxy
  • Baxter Acquires SuppreMol GmbH
  • Baxalta to Separate from Baxter and Change Headquarters
  • Matinas BioPharma Holdings Acquires Aquarius BioTechnologies
  • 3SBio Acquires Sirton Pharmaceuticals SpA
  • Pfizer to Acquire Hospira
  • Roche to Acquire Trophos
  • Novartis Completes Transaction with GSK
  • Johnson & Johnson Forms Ebola Vaccine Development Consortia
  • Boehringer Ingelheim and Sanofi Enter Strategic Manufacturing Agreement
  • OnCore Biopharma and Tekmira Enter Merger Agreement
  • Regado Biosciences and Tobira Enter Merger Agreement
  • WuXi PharmaTech Acquires NextCODE Health
  • Adaptive Biotechnologies to Acquire Sequenta
  • Cardio3 BioSciences Acquires OnCyte
  • FUJIFILM Diosynth Biotechnologies Acquires Kalon Biotherapeutics
  • Prima BioMed Completes Acquisition of Immutep
  • BioMarin Pharmaceutical Acquires ProSensa Holding
  • Ricerca Biosciences Acquired by Investment Group Main Market Partners
  • GE Healthcare Life Sciences to Open Biopharmaceutical Laboratory in Turkey
  • Johnson & Johnson Acquires Alios BioPharma
  • PDL Biopharma Acquires Part of Cerdelga Royalties
  • DPx Holdings B.V. Acquires Gallus BioPharmaceuticals
  • Sunshine Biopharma Forms Canadian Subsidiary
  • Albany Molecular Research Inc. (AMRI) Acquires OSO Biopharmaceuticals
  • Pall Corporation Acquires New Biopharmaceutical Production Technologies
  • Actavis Plc. Acquires Forest Laboratories
  • Roche to Acquire InterMune
  • CSL Acquires Influenza Vaccines Business of Novartis

8. FOCUS ON SELECT GLOBAL PLAYERS

  • AbbVie, Inc. (US)
  • Anavex Life Sciences Corp. (US)
  • Baxter International, Inc. (US)
  • Bayer HealthCare Pharmaceuticals, Inc. (US)
  • Biocon (India)
  • Eli Lilly (US)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Genentech (US)
  • GlaxoSmithKline (UK)
  • Janssen Biotech, Inc. (US)
  • Kemwell Biopharma (India)
  • Novartis (Switzerland)
  • Sandoz
  • Pfizer, Inc. (US)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Sanofi S.A. (France)

9. GLOBAL MARKET PERSPECTIVE

    • Table 26: World Recent Past, Current & Future Analysis for Biopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 27: World Historic Review for Biopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
    • Table 28: World 14-Year Perspective for Biopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)
  • Biopharmaceuticals Market by Product Segment
    • Table 29: World Recent Past, Current & Future Analysis for Recombinant Protein by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 30: World Historic Review for Recombinant Protein by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
    • Table 31: World 14-Year Perspective for Recombinant Protein by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)
    • Table 32: World Recent Past, Current & Future Analysis for Monoclonal Antibodies (mAbs) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 33: World Historic Review for Monoclonal Antibodies (mAbs) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
    • Table 34: World 14-Year Perspective for Monoclonal Antibodies (mAbs) by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)
    • Table 35: World Recent Past, Current & Future Analysis for Insulin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 36: World Historic Review for Insulin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
    • Table 37: World 14-Year Perspective for Insulin by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)
    • Table 38: World Recent Past, Current & Future Analysis for Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 39: World Historic Review for Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
    • Table 40: World 14-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • United States: The Largest Biopharmaceutical Market Globally
    • Table 41: No. of Biologics Approved by the Center for Biologics Evaluation and Research (CBER): 2003-2013 (includes corresponding Graph/Chart)
    • A R&D Driven Industry
    • Impending Patent Expiries
    • Table 42: Leading US Biopharmaceuticals by Revenue (in US$ Billion) and Year of Patent Expiry (includes corresponding Graph/Chart)
    • Biosimilars and the Implications of the BPCI Act
    • Segment Analysis
      • Monoclonal Antibodies
      • Opportunity Indicators
      • Rheumatoid Arthritis Incidence
    • Table 43: Rheumatoid Arthritis Prevalence in the US in Millions (2010-2030) (includes corresponding Graph/Chart)
    • Table 44: The US Cancer Incidence by Gender (2014): No. of Reported New Cases for Men and Women (includes corresponding Graph/Chart)
    • Table 45: The US Cancer Incidence by Affected Site (2014): Number of New Cancer Cases (includes corresponding Graph/Chart)
      • Recombinant Proteins
      • Erythropoietin (EPO) Market: Amgen Continues to Dominate
      • Interferon Market: An Insight
      • Colony Stimulating Factors (CSF) Market: An Overview
    • Table 46: The US Short Acting Granulocyte Colony Stimulating Factors (G-CSFs) Market (2014 & 2020): Percentage Share Breakdown of Volume Sales for HSP Nivestim, Neupogen, Sandoz EP2006, and TEVA Granix (includes corresponding Graph/Chart)
    • Table 47: The US Long Acting Granulocyte Colony Stimulating Factors (G-CSFs) Market (2014 & 2020): Percentage Share Breakdown of Volume Sales for HSP peg-Filgrastim, Neulasta, Sandoz LA-EP2006, and TEVA Balugrastim (includes corresponding Graph/Chart)
      • Vaccines Industry in the US
    • Federal Research & Grants
      • National Cancer Institute
      • National Institutes of Health (NIH)
      • Pediatric Vaccines Market Witnesses Rapid Growth
      • Opportunity Indicator
    • Table 48: Number of Reported Cases for Vaccine-Preventable Diseases in American Regions (includes corresponding Graph/Chart)
    • Table 49: Routine Immunization Coverage in the US (2011-2013): Percentage of Live Births/New Borns/Infants/Children Vaccinated (includes corresponding Graph/Chart)
    • Select Market Trends
      • Manufacturers Shift Focus to Small Bioreactors
      • Biosimilar Developers Face Higher Litigation Risks
      • Varying Biosimilar Prescription Rules across the Country
    • Regulatory Scenario
      • Combination Products Pose Challenges to Manufacturers
      • FDA Efforts to Mitigate Concerns
      • FDA Announces New Labeling Guidelines for Biologics and Prescription Drugs
    • Product Launches
    • Strategic Corporate Developments
    • Select Key Players
  • B. Market Analytics
    • Table 50: The US Recent Past, Current & Future Analysis for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 51: The US Historic Review for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
    • Table 52: The US 14-Year Perspective for Biopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Lucrative Partnership Opportunities for Global Players
    • Mabs Lead, Insulin Exhibits Faster Growth
    • Table 53: Prevalence of Diabetes Mellitus in Canada (2013 & 2035): Number of People with DM (in Thousands) in the 20-79 Age Group (includes corresponding Graph/Chart)
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 54: Canadian Recent Past, Current & Future Analysis for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 55: Canadian Historic Review for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
    • Table 56: Canadian 14-Year Perspective for Biopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Erythropoietin Market
      • Leading EPO Drugs in Japan
    • HCV Infection: Combination Therapy Dominates
    • Diabetes Prevalence: Opportunity Indicator for the Insulin Market
    • Table 57: Prevalence of Diabetes Mellitus in Japan (2013): Number of People with DM (in thousands) by Age Group (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Table 58: Japanese Recent Past, Current & Future Analysis for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 59: Japanese Historic Review for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
    • Table 60: Japanese 14-Year Perspective for Biopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Funding Challenges Faced by Biopharmaceutical Startups
      • Healthcare Agencies Looking to Embrace Biosimilars to Cut Healthcare Costs
    • Table 61: European Biosimilar Market by Leading Player (2014): Percentage Market Share of Value Sales for Hospira, Sandoz, Teva, and Others (includes corresponding Graph/Chart)
    • Table 62: Biosimilar Penetration in Select EU Countries (2013)
      • Biosimilars Currently Licensed in Europe
    • Regulatory Scenario
    • Erythropoietin Market
      • Leading EPO Drugs in Europe
  • B. Market Analytics
    • Table 63: European Recent Past, Current & Future Analysis for Biopharmaceuticals by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 64: European Historic Review for Biopharmaceuticals by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
    • Table 65: European 14-Year Perspective for Biopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)
    • Table 66: European Recent Past, Current & Future Analysis for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 67: European Historic Review for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
    • Table 68: European 14-Year Perspective for Biopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Sanofi S.A. - A Key Player
  • B. Market Analytics
    • Table 69: French Recent Past, Current & Future Analysis for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 70: French Historic Review for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
    • Table 71: French 14-Year Perspective for Biopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 72: German Recent Past, Current & Future Analysis for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 73: German Historic Review for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
    • Table 74: German 14-Year Perspective for Biopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

4c. ITALY

  • Market Analysis
    • Table 75: Italian Recent Past, Current & Future Analysis for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 76: Italian Historic Review for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
    • Table 77: Italian 14-Year Perspective for Biopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • A. Market Analysis
    • Strategic Corporate Development
    • Glaxosmithkline - A Key Player
  • B. Market Analytics
    • Table 78: The UK Recent Past, Current & Future Analysis for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 79: The UK Historic Review for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
    • Table 80: The UK 14-Year Perspective for Biopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

4e. SPAIN

  • Market Analysis
    • Table 81: Spanish Recent Past, Current & Future Analysis for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 82: Spanish Historic Review for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
    • Table 83: Spanish 14-Year Perspective for Biopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

4f. RUSSIA

  • A. Market Analysis
    • Russia Sets Eyes on Emerging as a Notable Pharmaceutical Market
    • Encouraging Local Manufacturing
    • Challenges - Need for Extensive R&D
  • B. Market Analytics
    • Table 84: Russian Recent Past, Current & Future Analysis for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 85: Russian Historic Review for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
    • Table 86: Russian 14-Year Perspective for Biopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

4g. REST OF EUROPE

  • A. Market Analysis
    • Product Launches
    • Strategic Corporate Developments
    • Select Key Players
  • B. Market Analytics
    • Table 87: Rest of European Recent Past, Current & Future Analysis for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 88: Rest of European Historic Review for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
    • Table 89: Rest of European 14-Year Perspective for Biopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Regional Biopharma Players Gain Strength by Innovation and Partnerships
    • Asia Set to Emerge as Preferred Outsourcing Destination for Biopharma Manufacturing
      • Availability of Scientific Talent - Major Advantage for India
      • Primary Challenges for Asian CMOs
    • China - An Untapped Market for Antitumor mAbs
      • List of Anti-Cancer Monoclonal antibodies Approved by China Food & Drug Administration
    • Table 90: Chinese Biopharmaceuticals Market by Segment (2014): Percentage Share Breakdown of Value Sales for EPO, G-CSF, Insulin, Interferon, Interleukin, mAb, Nerve Growth Factors, and Others (includes corresponding Graph/Chart)
    • Chinese Erythropoietin Market
    • Table 91: Leading Players in the Chinese EPO Market (2014): Percentage Share Breakdown of Value Sales for 3SBio, Beijing Sihuan, Harbin Pharma, Nanjin Huaxin Pharma, and Others (includes corresponding Graph/Chart)
    • Injectable Interferons: The Only Treatment for HCV Patients
    • Table 92: Interferon Market in China (2014): Percentage Share Breakdown of Value Sales by Type of Interferon (includes corresponding Graph/Chart)
    • Table 93: Leading Players in the Chinese Interferons Market (2014): Percentage Share Breakdown of Value Sales for Hualida Bio, Huaxin Bio, Merck, Roche, Sinovac, Tri-Prime Gene, and Others (includes corresponding Graph/Chart)
    • Hepatitis B Market: Smaller Role of Interferons
    • G-CSF Market: Competitive Landscape
    • Table 94: G-CSF Market in China by Agent (2014): Percentage Share Breakdown of Revenues for Filgrastim, Lenograstim, Molgramostim, Nartograstim, and Others (includes corresponding Graph/Chart)
    • Table 95: Leading Manufacturers in the Chinese G-CSF Market (2014): Percentage Share Breakdown of Revenues for Hangzhou Jiuyuan, Jiangsu Wuzhong Pharma, Qilu Pharma, Roche, Xiamen Amoytop Bio, Xiehe Fajio Qilin, and Others (includes corresponding Graph/Chart)
    • Interleukins Market
    • Table 96: Interleukins Market in China (2014): Percentage Share Breakdown of Value Sales by Type - Interleukin-11 and Interleukin-2 (includes corresponding Graph/Chart)
    • Table 97: Leading Players in the Chinese Interleukins Market (2014): Percentage Share Breakdown of Value Sales for E China Pharm, Four Rings, QG Pharm, Qilu Pharm, SL Pharm, and Others (includes corresponding Graph/Chart)
    • Cell Therapies Gaining Ground in Korea
    • Product Launches
    • Strategic Corporate Developments
    • Select Key Players
  • B. Market Analytics
    • Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 99: Asia-Pacific Historic Review for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
    • Table 100: Asia-Pacific 14-Year Perspective for Biopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

6. REST OF WORLD

  • A. Market Analysis
    • Lack of Access Impedes Market in Developing Economies
    • Interferons Widely Used in HCV Therapeutics in Brazil
    • Product Launches
  • B. Market Analytics
    • Table 101: Rest of World Recent Past, Current & Future Analysis for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 102: Rest of World Historic Review for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
    • Table 103: Rest of World 14-Year Perspective for Biopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Back to Top